SFSIG
XLRN

San Francisco Sentry Investment Group’s Acceleron Pharma XLRN Stock Holding History

San Francisco Sentry Investment Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-18
Closed -$1K – 1095
2018
Q4 		$1K Buy
+18
New +$899 ﹤0.01% 948

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

San Francisco Sentry Investment Group's XLRN Position: Q1 2019 in Review

San Francisco Sentry Investment Group sold out of Acceleron Pharma (XLRN) in Q1 2019, closing a stake of 18 shares — an estimated $1K sold.

San Francisco Sentry Investment Group first reported a position in XLRN in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 171 funds tracked by Wall St. Rank hold XLRN as of Q1 2019.

  • San Francisco Sentry Investment Group reported no remaining Acceleron Pharma position as of Q1 2019 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 18 Acceleron Pharma shares in Q1 2019, an estimated $1K.
  • San Francisco Sentry Investment Group first reported a position in Acceleron Pharma in Q4 2018 and held it in 1 quarter.
  • San Francisco Sentry Investment Group's Acceleron Pharma position peaked at $1K in Q4 2018.
  • 171 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2019.

Based on San Francisco Sentry Investment Group's 13F filing for Q1 2019, filed 8 May 2019.